MedicinalProductInteraction - FHIR Resource (r4)


This MedicinalProductInteraction Resource uses the FHIR API standard for access and structure.

Validate an MedicinalProductInteraction FHIR Resource (r4)



Resource Attributes

AttributeField is listTypeDescription
descriptionfalsestring# The interaction described
effectfalseCodeableConcept# The effect of the interaction, for example "reduced gastric absorption of primary medication"
incidencefalseCodeableConcept# The incidence of the interaction, e.g. theoretical, observed
interactanttrueData Type# The specific medication, food or laboratory test that interacts
managementfalseCodeableConcept# Actions for managing the interaction
subjecttrueReference# The medication for which this is a described interaction
typefalseCodeableConcept# The type of the interaction e.g. drug-drug interaction, drug-food interaction, drug-lab test interaction

MedicinalProductInteraction Example

{
  "resourceType": "MedicinalProductInteraction",
  "id": "example",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div>"
  },
  "description": "Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.",
  "interactant": [
    {
      "itemCodeableConcept": {
        "coding": [
          {
            "system": "http://ema.europa.eu/example/interactant",
            "code": "ketoconazole"
          }
        ]
      }
    },
    {
      "itemCodeableConcept": {
        "coding": [
          {
            "system": "http://ema.europa.eu/example/interactant",
            "code": "itraconazole"
          }
        ]
      }
    }
  ],
  "type": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/interactionsType",
        "code": "StrongInhibitorofCYP3A4"
      }
    ]
  },
  "effect": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/interactionseffect",
        "code": "Increasedplasmaconcentrations"
      }
    ]
  },
  "management": {
    "text": "Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"
  }
}

MedicinalProductInteraction Structure

{
  "resourceType" : "MedicinalProductInteraction",
  // from Resource: id, meta, implicitRules, and language
  // from DomainResource: text, contained, extension, and modifierExtension
  "subject" : [{ Reference(MedicinalProduct|Medication|Substance) }], // The medication for which this is a described interaction
  "description" : "<string>", // The interaction described
  "interactant" : [{ // The specific medication, food or laboratory test that interacts
    // item[x]: The specific medication, food or laboratory test that interacts. One of these 2:
    "itemReference" : { Reference(MedicinalProduct|Medication|Substance|
    ObservationDefinition) }
    "itemCodeableConcept" : { CodeableConcept }
  }],
  "type" : { CodeableConcept }, // The type of the interaction e.g. drug-drug interaction, drug-food interaction, drug-lab test interaction
  "effect" : { CodeableConcept }, // The effect of the interaction, for example "reduced gastric absorption of primary medication"
  "incidence" : { CodeableConcept }, // The incidence of the interaction, e.g. theoretical, observed
  "management" : { CodeableConcept } // Actions for managing the interaction
}

MedicinalProductInteraction Search Parameters

The following search parameters can be used to query MedicinalProductInteraction resources. Just submit them like so:

https://api.1up.health/fhir/r4/MedicinalProductInteraction?query-param=queryvalue
Search ParameterField TypeResource Fields Searched
subjectreferencesubject